Prolonged Response of Relapsed High Grade Serous Ovarian Carcinoma to the Oral Angiokinase Inhibitor Nintedanib in a Patient with a Germline BRCA1 Mutation
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.
References
1.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G
. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8.
DOI: 10.1200/JCO.2013.51.4489.
View
2.
Tarnowski B, Chudecka-Glaz A, Gorski B, Rzepka-Gorska I
. Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3):287-8.
DOI: 10.1007/s10549-004-0779-0.
View
3.
Ledermann J, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I
. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011; 29(28):3798-804.
DOI: 10.1200/JCO.2010.33.5208.
View
4.
Kang H, Kim H, Rih J, Mattson T, Kim K, Cho C
. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006; 281(19):13047-13056.
DOI: 10.1074/jbc.M513033200.
View
5.
Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H
. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83.
DOI: 10.1056/NEJMoa1104390.
View